Questcor to Participate in Upcoming Conferences

UNION CITY, Calif., July 29 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will participate in the following upcoming investor conferences:

Attendance at these conferences is by invitation only. Don M. Bailey, President and Chief Executive Officer, and Dr. David Young, Chief Scientific Officer, will discuss the Company's business strategy and historical financial performance.

About Questcor

Questcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.